Charles River Laboratories International (NYSE:CRL) Price Target Cut to $160.00 by Analysts at JPMorgan Chase & Co.

Charles River Laboratories International (NYSE:CRL) had its price objective trimmed by JPMorgan Chase & Co. from $165.00 to $160.00 in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a neutral rating on the medical research company’s stock.

CRL has been the topic of several other research reports. UBS Group boosted their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Barclays lowered their price target on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, February 19th. Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, April 8th. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, December 15th. Finally, TD Cowen lowered their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average price target of $204.64.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $178.06 on Monday. Charles River Laboratories International has a 52-week low of $99.80 and a 52-week high of $228.88. The firm has a market capitalization of $8.79 billion, a price-to-earnings ratio of -60.16, a PEG ratio of 2.12 and a beta of 1.61. The company has a fifty day simple moving average of $169.50 and a 200-day simple moving average of $182.41. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company’s revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Invesco Ltd. lifted its position in shares of Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $176,478,000. Victory Capital Management Inc. lifted its position in shares of Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after purchasing an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after purchasing an additional 575,039 shares in the last quarter. Finally, National Bank of Canada FI lifted its position in shares of Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after purchasing an additional 511,901 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.